Tecfidera

Chemical Namedimethyl fumarate
Dosage FormCapsule (oral; 120 mg, 240 mg)
Drug ClassModulators
SystemNervous
CompanyBiogen
Approval Year2013

Indication

  • For the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Last updated on 6/22/2022

More on this drug: Clinical Trials

Document TitleYearSource
Tecfidera (dimethyl fumarate) Prescribing Information.2022Biogen Idec Inc., Cambridge, MA
Document TitleYearSource
Assessment report: Tecfidera. 2022EMA

Have we missed a study, or would you like to comment on a study?